InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$172.97

2026-10-16

Market Cap

$48.8B

Volume

2.9M

52-Wk High

$177.47

52-Wk Low

$108.35

Trailing PE

34.0

P/S

6.62

Gross Margin

53.7%

Net Margin

19.5%

ROE

20%

ROIC

12%

Piotroski

6/9

Altman Z

5.8

1-Yr Return

+22.6%

5-Yr Return

+154.3%

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

SectorHealthcareIndustryMedical - Diagnostics & ResearchExchangeNYSEMarket Cap$48.8BEmployees18,100 (SEC-filed)CEOPadraig McDonnellIPO1999-11-18CountryUS

5301 Stevens Creek Boulevard, Santa Clara, CA 95051 · Tel 800 227 9770 · agilent.com

INSIDERSTREET SCORE71 / 100Street mean $177.67 (12 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$0M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · A +22.6% · S&P 500 +15.9% · spread +6.7pp

7 Years vs S&P 500 · A +154.3% · S&P 500 +189.9% · spread -35.5pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE71of 100

Score Breakdown

Profitability	74/100
Growth	60/100
Momentum	82/100
Quality	81/100
Earnings Quality	74/100
Balance Sheet	76/100
Value	55/100
Risk (safety)	100/100
Overall	71.2/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
IDXX	80
IQV	56
WAT	47
NTRA	50
ILMN	58
MTD	63
A	71

IS Score Trend — quarterly

15 quarters, 23 Q1 to 26 Q3. Peak 71 in 26 Q3, latest 71 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY71 / 100IS Score 71.2 / 100 · +0.0 from peak of 71

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 86 / 100 · Power +72 · 21 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 71 and price structure at 86 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 71.2	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 62 → 59 → 70 → 71	the direction matters more than the level
Technical vote share back above 50%	now 91%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,139 → now 1,126	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)0 buysnone disclosed

Insider Buys (180d)0none disclosed

ETF Funds (30d)1213 up / 1130 downnet +83 funds

Institutions Added (13F)56managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,139 · latest 1,126 (-13 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,126	263.6M	$33.4B	93.5%
2026 Q1	1,070	253.8M	$27.3B	90.0%
2025 Q4	1,139	256.3M	$33.0B	90.9%
2025 Q3	1,030	250.7M	$30.5B	88.9%
2025 Q2	1,001	255.3M	$28.4B	90.5%
2025 Q1	1,014	253.2M	$28.1B	89.8%
2024 Q4	1,071	252.8M	$32.0B	89.6%
2024 Q3	1,044	251.1M	$34.8B	89.0%
2024 Q2	1,004	254.2M	$30.8B	90.1%
2024 Q1	1,012	260.3M	$34.5B	92.3%
2023 Q4	999	256.6M	$32.6B	91.0%
2023 Q3	911	251.8M	$26.1B	89.3%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Boehnlein Glenn S	director	2026-09-08	A-Award	817	$0.12M	817
Dolsten Mikael	director	2026-09-04	SELL	634	$0.10M	4,924
Kirkwood Jonah Prevost	Senior Vice President	2026-06-26	TAX W/H	30	$0.00M	14,108
Mcdonnell Padraig	director, President and CEO	2026-06-03	TAX W/H	418	$0.06M	65,842
Dolsten Mikael	director	2026-05-29	SELL	1,600	$0.22M	5,548
Buckner Michael Steven	Senior Vice President	2026-05-19	A-Award	8,872	—	8,887
May Simon	Senior Vice President	2026-05-08	TAX W/H	368	$0.04M	14,015
Henson Meghan	Senior Vice President	2026-03-31	TAX W/H	153	$0.02M	6,890

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	2	2,234	$0.3M	Counted
F — Tax withholding	9	2,757	$0.3M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$0.3M2 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-09-04	Dolsten Mikael	634	$0.1M
2026-05-29	Dolsten Mikael	1,600	$0.2M
2025-12-01	Dolsten Mikael	2,600	$0.4M
2025-11-26	Gonsalves Rodney	3,000	$0.5M
Trailing 12 mo	11 filings	94,044	$12M

Filed	Form	Reporting person	% of class	Shares
2026-04-28	SCHEDULE 13G	Vanguard Portfolio Management	5.09%	14.4M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-04-17	SCHEDULE 13G/A	BlackRock, Inc.	8.30%	23.6M sh
2025-02-13	SCHEDULE 13G/A	Massachusetts Financial Services Company	4.40%	12.4M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	SELL	$1,001 - $15,000	2026-01-29	2026-02-10
Ro Khanna	House	BUY	$1,001 - $15,000	2025-09-29	2025-10-03
Julie Johnson	House	SELL	$1,001 - $15,000	2025-09-23	2026-08-06
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-05-03	2024-06-14
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-05-03	2024-06-13
Thomas Hawley Tuberville	Senate	SELL	$1,001 - $15,000	2024-05-03	2024-06-13

House 12-Mo8 trades4 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,070

13F Shares254M90.0% of shares out

New / Closed109 / 159positions, QoQ

Increased / Reduced402 / 372positions, QoQ

Put/Call (13F)1.16option positions

Free Float99.6%281M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Fenimore Asset Management Inc	558,284	$96M
Davenport & Co Llc	346,076	$60M
Godsey & Gibb, Inc	178,388	$31M
Wealth Enhancement Advisory Servic	113,001	$18M
Fjarde Ap-Fonden /Fourth Swedish N	102,739	$18M
Generate Investment Management Ltd	89,766	$15M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$1.5B
VTI	0.1%	$1.5B
VTSAX	0.1%	$1.5B
VSMPX	0.1%	$1.5B
VOO	0.1%	$1.3B
VFFSX	0.1%	$1.3B

13F Filers Holding A — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session56.6%2026-10-15

20-Day Avg45.3%50-day 51.0%

TrendFalling20d vs 50d

By Market CenterQ: 55% · N: 82% · B: 74%latest session

Weekly Notional ($B)

Where A Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	2.5M	42 sh
Ubsa Ubs Ats	2.1M	47 sh
Sgmt Sigma X2	1.4M	39 sh
Ebxl Level Ats	1.1M	28 sh
Mstx Ms Trajectory Cross (Ats-1)	1.0M	34 sh
Mspl Ms Pool (Ats-4)	0.7M	147 sh

Where a dollar of Agilent Technologies, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
Americas	$2.8B	40%
Asia Pacific	$2.2B	32%
Europe	$1.9B	28%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

A (live moat model)Peer median: IDXX · IQV · WAT · NTRA · ILMN

Component scores from the live moat model. Peer median illustrative.

Moat score 38/100 — None; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Padraig McDonnell	Chief Executive Officer, President & Director
Simon May	Senior VP and President of Life Sciences & Diagnostics Markets Group
Bret DiMarco	Special Advisor
Michael Buckner	Senior Vice President, Chief Legal Officer, & Secretary

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)3 of 6recent quarters

Avg Surprise+3.0%

Next Report2026-11-23

Income Quality1.12OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+18.4%	+8.4%	-0.2%	-4.7%	+6.7%
Gross profit	+20.1%	+9.2%	-6.9%	+2.0%	+3.1%
Operating income	+59.2%	+20.1%	-16.6%	+10.2%	-0.6%
Net income	+68.3%	+3.6%	-1.1%	+4.0%	+1.1%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	6.3	6.8	6.8	6.5	6.9
Cost of revenue	2.9	3.1	3.4	3.0	3.3
Gross profit	3.4	3.7	3.5	3.5	3.6
R&D expense	0.4	0.5	0.5	0.5	0.5
SG&A expense	1.6	1.6	1.6	1.5	1.7
Operating income	1.3	1.6	1.4	1.5	1.5
EBITDA	1.8	1.9	1.7	1.9	1.8
D&A	0.3	0.3	0.3	0.3	0.3
Pretax income	1.4	1.5	1.3	1.5	1.4
Income tax	0.2	0.2	0.1	0.2	0.1
Net income	1.2	1.3	1.2	1.3	1.3
Diluted EPS ($)	3.94	4.18	4.19	4.43	4.57
Diluted shares (M)	307	300	296	291	284

Operating CF$2B

CapEx$0B

Free cash flow$1B

SBC$0B

Buybacks$0B

Net cash change$0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	1.1	1.6	1.3	1.8
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	1.4	1.3	1.3	1.5
Total current assets	3.8	4.2	4.0	4.6
PP&E (net)	1.1	1.4	2.0	2.0
Goodwill + intangibles	4.8	4.4	5.0	4.9
Total assets	10.5	10.8	11.8	12.7
Accounts payable	0.6	0.4	0.5	0.6
Short-term debt	0.0	0.0	0.0	0.3
Deferred revenue	0.5	0.5	0.5	0.6
Total current liabilities	1.9	1.6	1.9	2.3
Long-term debt	2.7	2.7	3.3	3.1
Total liabilities	5.2	4.9	5.9	6.0
Shareholders' equity	5.3	5.8	5.9	6.7

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	1.3	1.2	1.3	0.4
D&A	0.3	0.3	0.3	0.3
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	(0.5)	(0.1)	0.1	(0.1)
Operating cash flow	1.3	1.8	1.8	1.6
Capital expenditures	(0.3)	(0.3)	(0.4)	(0.4)
Investing cash flow	(0.3)	(0.3)	(1.3)	(0.4)
Buybacks	(1.1)	(0.6)	(1.2)	(0.4)
Dividends paid	(0.2)	(0.3)	(0.3)	(0.3)
Debt issuance / (repay)	0.0	(0.0)	0.6	(0.0)
Financing cash flow	(1.4)	(0.9)	(0.8)	(0.7)
Free cash flow	1.0	1.5	1.4	1.2

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	23.6%	23.5%	22.2%	22.0%	20.6%	20%
ROA	11.9%	11.8%	11.6%	11.4%	10.6%	10.3%
ROIC	18.3%	19.2%	17.9%	15.5%	16.2%	11.9%
Gross margin	53.9%	54.4%	50.7%	54.3%	52.4%	53.7%
Operating margin	21.3%	23.6%	19.8%	22.9%	21.3%	22.2%
Net margin	19.1%	18.3%	18.1%	19.8%	18.8%	19.5%
EBITDA margin	27.9%	27.8%	24.9%	28.8%	26.4%	27.6%
FCF margin	20.5%	14.9%	21.6%	21.1%	16.6%	—
VALUATION
P/E	38.59	32.16	24.06	29.18	31.90	34.0
P/B	8.66	7.60	5.11	6.38	6.17	6.6
P/S	7.39	5.89	4.37	5.78	5.98	6.62
P/FCF	36.03	39.50	20.24	27.39	36.08	34.0
EV/EBITDA	27.15	22.06	18.17	21.51	23.50	25.0
EV/Revenue	7.57	6.14	4.53	6.12	6.21	6.9
Earnings yield	2.6%	3.1%	4.2%	3.4%	3.1%	2.95%
FCF yield	2.8%	2.5%	4.9%	3.7%	2.8%	2.94%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	2.22	2.03	2.61	2.09	1.96	2.05
Quick ratio	1.74	1.47	1.97	1.57	1.52	1.56
Debt / equity	0.51	0.52	0.47	0.61	0.50	0.54
Debt / assets	25.5%	26.3%	25.4%	30.2%	26.4%	28.3%
Net debt / EBITDA	0.65	0.90	0.67	1.21	0.85	1.08
Interest coverage	17.79	18.90	15.09	16.62	13.81	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.62	0.64	0.64	0.58	0.57	0.53
Receivables turnover	5.72	5.31	5.07	4.98	4.94	5.0
DSO (days)	64	69	72	73	74	73
DPO (days)	50	60	54	59	61	65
Cash conversion cycle	111	118	130	139	124	128
GROWTH (YoY)
Revenue growth	18.4%	8.4%	-0.2%	-4.7%	6.7%	—
Net income growth	68.3%	3.6%	-1.1%	4.0%	1.1%	—
EPS growth	71.6%	6.1%	0.6%	4.7%	3.6%	—
FCF growth	61.6%	-21.2%	44.4%	-6.9%	-16.1%	—
PER SHARE ($)
EPS (diluted, TTM)	3.97	4.21	4.23	4.43	4.59	5.11
Book value / share	17.67	17.80	19.95	20.27	23.74	26.11
Revenue / share	20.72	22.98	23.32	22.37	24.46	26.14
FCF / share	4.25	3.43	5.03	4.72	4.06	5.09
Cash / share	5.16	3.53	5.43	4.57	6.30	6.23
SHAREHOLDER RETURN & SCORES
Buyback yield	1.7%	2.8%	1.9%	3.1%	1.0%	0.97%
Altman Z-Score	6.58	6.04	5.10	5.09	5.48	5.8
Piotroski F-Score	7	7	6	4	6	6/9
Beneish M-Score	-2.45	-2.35	-2.82	-2.59	-2.44	-2.45

Model	Score	Zone	Note
Piotroski F-Score	6 / 9	Middling
Altman Z-Score	5.8	Safe (>2.99)	Safe
Income quality	1.12	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.45	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.87
Interest burden	0.94
Operating margin	23.9%
Asset turnover	0.56×
Financial leverage	1.91×
= ROE	21%

Growth Quality (live)	Value
Revenue stability	0.63
Earnings stability	0.46
Earnings persistence	0.93
Revenue CAGR 3y	1.8%
EPS CAGR 3y	9.8%
FCF CAGR 3y	0.4%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.97%

Dividend Yield0.59%

Total Shareholder Return1.51%cash yield

SBC / Revenue1.8%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
IDXX	$44.1B	39.4	74%	27.8%	+12.8%	9/9	-12.1%
IQV	$43.9B	32.8	23%	5.9%	+8.2%	7/9	+29.8%
WAT	$42.9B	108.7	2%	-8.3%	+52.5%	5/9	+30.5%
NTRA	$56.7B	-289.3	-13%	-8.9%	+37.8%	6/9	+117.9%
ILMN	$39.6B	48.5	32%	17.9%	+4.9%	7/9	—
MTD	$32.5B	36.4	-736%	22.7%	+6.9%	8/9	—
DGX	$25.9B	24.6	14%	10.5%	+9.9%	8/9	—
LH	$25.8B	26.1	12%	8.0%	+6.4%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

41 Analysts

Str Sell (0)Sell (1)Hold (7)Buy (32)Str Buy (1)

Mean Target (qtr)$177.6712 targets

Target vs. Price+2.7%last-quarter mean

Next Report2026-11-23street $1.72

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$7.50B	$7.51B / $7.49B	$6.20	$6.29 / $6.19	12
FY2027	$7.99B	$8.03B / $7.95B	$6.74	$6.97 / $6.51	13
FY2028	$8.51B	$8.80B / $8.31B	$7.44	$8.00 / $6.92	7

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$192.50	+11.3%	2
Last Quarter	$177.67	+2.7%	12
Last Year	$171.00	-1.1%	32
All Time	$160.69	-7.1%	55

Rolling mean of published targets vs. last close $172.97. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

3/5

ROE

5/5

ROA

5/5

Debt/Eq

1/5

P/E

2/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

A +22.6% vs S&P 500 +15.9% — spread +6.7pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$170.41	+2.56	+1.50%	Above
SMA 50	$158.84	+14.13	+8.90%	Above
SMA 200	$134.46	+38.51	+28.64%	Above
EMA 9	$171.94	+1.03	+0.60%	Above
EMA 21	$168.16	+4.81	+2.86%	Above
EMA 50	$159.48	+13.49	+8.46%	Above
EMA 200	$140.83	+32.14	+22.82%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +7221 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%90

Volume 20%88

Volatility 10%83

Patterns 15%50

This Week91% bullishof 11 price-based votes

4 Weeks Ago100%-9 pts since

12 Weeks Ago91%+0 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$170.41

Price vs SMA 50$158.84

Price vs SMA 200$134.46

EMA 9/21 Cross171.9/168.2

SMA 50/200Golden

ADX DirectionADX 39

Supertrend$162

Parabolic SAR$164

SMA Slope0.820

RSI62.4

Stochastic K/D79/74

StochRSI K/D37/36

Williams %R-32

CCI96

TSI vs Signal29.1

CMO24.8

ROC3.23%

OBV SignalAccum

Chaikin MF0.180

MFI51

Force Index1M

Elder Ray Bull9.33

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 74

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$175.43 / $177.16 / $178.78	S1 / S2	$173.81 / $172.08
Bollinger (20,2)	$163.37 – $177.45	Squeeze	ON
52-wk range	$108.35 – $177.49	Off 52-wk high	-2.6%
ATR (14)	$4.58 (2.6%)	Historical vol	29.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+1.1%Jan50%

-3.4%Feb40%

+1.2%Mar57%

+0.8%Apr55%

+1.0%May50%

+0.0%Jun45%

+1.2%Jul60%

+1.1%Aug55%

+0.7%Sep55%

-0.2%Oct50%

+4.5%Nov85%

+1.4%Dec55%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	A	S&P 500
Weekly volatility (σ, 1y)	4.69%	1.83%
Best / worst week (1y)	+18.3% / -5.5%	—
Max drawdown (5y, monthly)	-36.4%	—
1-week VaR (95%)	-5.3%	—
Beta (5y)	1.24	1.00

A EQUITY WEATHER (LIVE)PARTLY CLOUDY · +24

Trend+50

Momentum+37

Volume+38

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 193 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+24.1+41.1 vs industry

Trend+49.6+56.8 vs industry

Momentum+36.9+63.8 vs industry

Volume+37.6+37.6 vs industry

Reading	A	Medical - Diagnostics & Research n=227	Healthcare n=5,272	All US symbols n=70,435
Overall	+24.1	-17.0	-24.0	-20.5
Trend	+49.6	-7.2	-25.6	-21.3
Momentum	+36.9	-27.0	-28.5	-15.8
Volume	+37.6	+0.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Padraig McDonnell President; Chief Executive	$12.8M	75% equity+incentive
Robert McMahon Former Senior Vice President;	$5.5M	72% equity+incentive
Simon May Senior Vice President, Agilent Pre	$3.9M	59% equity+incentive
Bret DiMarco Senior Vice President, Chief Le	$3.7M	67% equity+incentive
Angelica Riemann Senior Vice President, Agil	$3.2M	68% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	77
Social	70
Governance	63
Composite ESG	70

Composite ESG Trend

Filed	8-K contents	Items
2026-09-08	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-08-26	Earnings Release; Exhibits	2.02,9.01
2026-06-25	Material Agreement; Financial Obligation; Exhibits	1.01,2.03,9.01
2026-05-27	Earnings Release; Officer/Director Change; Exhibits	2.02,5.02,9.01
2026-05-04	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-04-06	Officer/Director Change; Exhibits	5.02,9.01
2026-04-03	Change in Control; Exhibits	5.01,9.01
2026-03-06	Departure/Election of Directors; Appointment of Officers; Financial St	5.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-23 to 2026-08-26
Analyst estimates	dim/forward_estimates	3 rows · 2026-10-31 to 2028-10-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	108 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-03-19 to 2026-09-08
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-02-13 to 2026-04-28
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Agilent Technologies, Inc. (A)

Institutions holding — 12 quarters

Agilent Technologies, Inc. (A)

Monthly Net Insider Flow (000 shares)

Signal Summary

Agilent Technologies, Inc. (A)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding A — quarterly

Institutional Put/Call — quarterly

Agilent Technologies, Inc. (A)

Where A Trades in the Dark

Agilent Technologies, Inc. (A)

3.8 · Employees (SEC filings)

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Balance Sheet — Full

Cash Flow Statement — Full

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Street Price Target — Trajectory

Third-Party Composite Rating

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Family Scores (site weights)

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A)